| pubmed-article:6424413 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C0053225 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C0017628 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C0038766 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C0001721 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C1709915 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C0332256 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C1879746 | lld:lifeskim |
| pubmed-article:6424413 | lifeskim:mentions | umls-concept:C1547011 | lld:lifeskim |
| pubmed-article:6424413 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:6424413 | pubmed:dateCreated | 1984-5-2 | lld:pubmed |
| pubmed-article:6424413 | pubmed:abstractText | HB 699 is a non-sulfonylurea acyl-amino-alkyl benzoic acid derivative, corresponding to a major part of the glibenclamide molecule. Basal insulin release (3 mmol/l glucose) as well as glucose-induced release (10 mmol/l glucose) were stimulated by 25 mumol/l and 200 mumol/l HB 699. HB 699 (200 mumol/l) had no effect on the osmotic swelling induced by hypoosmolarity (180 mosm/l). The results indicate that the glibenclamide-induced insulin release can be resolved in a "high-affinity" component, which correlates with increased osmotic resistance in the beta-cells and a "low-affinity" component not associated with increased osmotic resistance. It is suggested that the latter component may be due to the part of the glibenclamide molecule that corresponds to HB 699. | lld:pubmed |
| pubmed-article:6424413 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6424413 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6424413 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6424413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6424413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6424413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6424413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6424413 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6424413 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6424413 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:6424413 | pubmed:issn | 0001-6772 | lld:pubmed |
| pubmed-article:6424413 | pubmed:author | pubmed-author:SehlinJJ | lld:pubmed |
| pubmed-article:6424413 | pubmed:author | pubmed-author:NorlundLL | lld:pubmed |
| pubmed-article:6424413 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6424413 | pubmed:volume | 120 | lld:pubmed |
| pubmed-article:6424413 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6424413 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6424413 | pubmed:pagination | 283-6 | lld:pubmed |
| pubmed-article:6424413 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:meshHeading | pubmed-meshheading:6424413-... | lld:pubmed |
| pubmed-article:6424413 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6424413 | pubmed:articleTitle | The acyl-amino-alkyl benzoic acid residue and the sulfonylurea containing residue of glibenclamide affect different aspects of beta-cell function. | lld:pubmed |
| pubmed-article:6424413 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6424413 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6424413 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6424413 | lld:pubmed |
